<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02067104</url>
  </required_header>
  <id_info>
    <org_study_id>1401183410</org_study_id>
    <secondary_id>ML28585</secondary_id>
    <nct_id>NCT02067104</nct_id>
  </id_info>
  <brief_title>Vismodegib in Basal Cell Carcinomas (BCC) Chemoprevention</brief_title>
  <official_title>A Placebo Controlled Double-Blind Study to Evaluate the Efficacy of Vismodegib as Chemoprevention of New Bcc Development in High Risk Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Arizona</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Arizona</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a single site double blinded Phase II study to evaluate the chemopreventative&#xD;
      effectiveness of vismodegib in the treatment of subjects at high risk for developing basal&#xD;
      cell carcinomas (BCC).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this study will be to determine if vismodegib pulse therapy will&#xD;
      significantly reduce the incidence of newly diagnosed basal cell carcinomas (BCC) in high&#xD;
      risk individuals when compared with placebo, as measured by the incidence of biopsy confirmed&#xD;
      BCC over a 24 month period.&#xD;
&#xD;
      The secondary objective will be to determine that there will be no difference in the&#xD;
      incidence of newly diagnosed squamous cell carcinomas (SCC) in the same subjects receiving&#xD;
      vismodegib treatment when compared with placebo, as measured by the incidence of biopsy&#xD;
      confirmed SCC over the same 24 month period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Low enrollment&#xD;
  </why_stopped>
  <start_date type="Actual">February 17, 2014</start_date>
  <completion_date type="Actual">December 31, 2016</completion_date>
  <primary_completion_date type="Actual">December 31, 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Effect of Vismodegib Pulse Therapy on the Incidence of Newly Diagnosed Basal Cell Carcinomas (BCC)</measure>
    <time_frame>24 Months</time_frame>
    <description>Measured by the incidence of biopsy confirmed BCC over a 24 month period</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Incidence of Newly Diagnosed Squamous Cell Carcinomas (SCC) in the Same Subjects Receiving Vismodegib Treatment When Compared With Placebo</measure>
    <time_frame>24 Months</time_frame>
    <description>Measured by the incidence of biopsy confirmed SCC over the same 24 month period</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Basal Cell Carcinomas</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>receive 150 mg of oral placebo daily for a period of 2 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vismodegib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>receive 150 mg of vismodegib daily for a period of 2 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vismodegib</intervention_name>
    <description>Pulse therapy pattern of 2 months of daily treatment and 2 months of no treatment for 24 months.</description>
    <arm_group_label>Vismodegib</arm_group_label>
    <other_name>Erivedge</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Pulse therapy pattern of 2 months of daily treatment and 2 months of no treatment for 24 months.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed and dated informed consent document indicating that the subject (or legally&#xD;
             acceptable representative) has been informed of all pertinent aspects&#xD;
&#xD;
          -  Comply with scheduled visits, treatment plan, laboratory tests, and other study&#xD;
             procedures.&#xD;
&#xD;
          -  At least 18 years of age at the time of informed consent.&#xD;
&#xD;
          -  History of 3 or more biopsy confirmed BCCs in the preceding 2 years, calculated from 2&#xD;
             years prior to the screening visit.&#xD;
&#xD;
          -  No active skin cancers.&#xD;
&#xD;
          -  Women of reproductive potential must agree to use two forms of acceptable&#xD;
             contraception&#xD;
&#xD;
          -  Male subjects must agree to use condoms at all times, even after a vasectomy, during&#xD;
             sexual intercourse with female partners of reproductive potential during treatment&#xD;
             with vismodegib and for 2 months after the last dose to avoid exposing a pregnant&#xD;
             partner and the unborn fetus to vismodegib.&#xD;
&#xD;
          -  Male patients must agree not to donate sperm during the study and for 2 months after&#xD;
             discontinuation of vismodegib&#xD;
&#xD;
          -  Agreement not to donate blood or blood products during the study and for 7 months&#xD;
             after the last dose.&#xD;
&#xD;
          -  Ability to understand and the willingness to sign a written informed consent document&#xD;
             in English&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women who are pregnant or lactating, or planning pregnancy while enrolled in the study&#xD;
             or for 7 months after the last dose of the study drug.&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active&#xD;
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac&#xD;
             arrhythmia, or psychiatric illness/social situations that would limit compliance with&#xD;
             study requirements. Subjects with clinically stable chronic medical conditions&#xD;
             including, but not limited to, controlled hypertension, diabetes mellitus type II,&#xD;
             hypercholesterolemia, or osteoarthritis, will be allowed to enter the study.&#xD;
&#xD;
          -  Inability or unwillingness to swallow capsules.&#xD;
&#xD;
          -  Have a history of alcohol of substance abuse, unless in full remission for greater&#xD;
             than 6 months prior to the screening visit (Day 0) when the consent form is signed.&#xD;
&#xD;
          -  Known to be infected with human immunodeficiency virus (HIV), hepatitis B or hepatitis&#xD;
             C viruses.&#xD;
&#xD;
          -  Currently receiving vismodegib, biologics or chemotherapy&#xD;
&#xD;
          -  Currently undergoing treatment with photodynamic therapy, topical chemotherapy agents&#xD;
             including Imiquimod, fluorouracil&#xD;
&#xD;
          -  Subjects who have Gorlins syndrome&#xD;
&#xD;
          -  Subjects who have received any type of solid organ transplant&#xD;
&#xD;
          -  Subjects taking immunosuppressive medications at the screening visit. (Day 0)&#xD;
&#xD;
          -  Participation in other study using an investigational or experimental therapy or&#xD;
             procedure within 4 weeks or 5 half-lives (whichever is longer) before the screening&#xD;
             visit and/or during study participation. Subjects cannot participate in studies of&#xD;
             other investigational or experimental therapies or procedures at any time during their&#xD;
             participation in this study.&#xD;
&#xD;
          -  Other severe acute or chronic medical or psychiatric condition or laboratory&#xD;
             abnormality that may increase the risk associated with study participation or&#xD;
             investigational product administration or may interfere with the interpretation of&#xD;
             study results and, in the judgment of the investigator, would make the subject&#xD;
             inappropriate for entry into this study.&#xD;
&#xD;
          -  Subjects unable or unwilling to comply with the study visit schedule and requirements&#xD;
             of the study&#xD;
&#xD;
          -  Subjects unable to speak and read the English language&#xD;
&#xD;
          -  A subject who, in the opinion of the sponsor-investigator will be uncooperative or&#xD;
             unable to comply with study procedures.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clara Curiel-Lewandroski</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Arizona</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Arizona Cancer Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>February 18, 2014</study_first_submitted>
  <study_first_submitted_qc>February 19, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 20, 2014</study_first_posted>
  <results_first_submitted>July 9, 2019</results_first_submitted>
  <results_first_submitted_qc>July 9, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">July 31, 2019</results_first_posted>
  <last_update_submitted>July 30, 2019</last_update_submitted>
  <last_update_submitted_qc>July 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Basal Cell</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>receive 150 mg of oral placebo daily for a period of 2 months&#xD;
Placebo: Pulse therapy pattern of 2 months of daily treatment and 2 months of no treatment for 24 months.</description>
        </group>
        <group group_id="P2">
          <title>Vismodegib</title>
          <description>receive 150 mg of vismodegib daily for a period of 2 months&#xD;
Vismodegib: Pulse therapy pattern of 2 months of daily treatment and 2 months of no treatment for 24 months.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Study termination due to low accrual</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>receive 150 mg of oral placebo daily for a period of 2 months&#xD;
Placebo: Pulse therapy pattern of 2 months of daily treatment and 2 months of no treatment for 24 months.</description>
        </group>
        <group group_id="B2">
          <title>Vismodegib</title>
          <description>receive 150 mg of vismodegib daily for a period of 2 months&#xD;
Vismodegib: Pulse therapy pattern of 2 months of daily treatment and 2 months of no treatment for 24 months.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
            <count group_id="B2" value="5"/>
            <count group_id="B3" value="9"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Effect of Vismodegib Pulse Therapy on the Incidence of Newly Diagnosed Basal Cell Carcinomas (BCC)</title>
        <description>Measured by the incidence of biopsy confirmed BCC over a 24 month period</description>
        <time_frame>24 Months</time_frame>
        <population>Early study termination due to low accrual. No data analyzed; no results.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>receive 150 mg of oral placebo daily for a period of 2 months&#xD;
Placebo: Pulse therapy pattern of 2 months of daily treatment and 2 months of no treatment for 24 months.</description>
          </group>
          <group group_id="O2">
            <title>Vismodegib</title>
            <description>receive 150 mg of vismodegib daily for a period of 2 months&#xD;
Vismodegib: Pulse therapy pattern of 2 months of daily treatment and 2 months of no treatment for 24 months.</description>
          </group>
        </group_list>
        <measure>
          <title>The Effect of Vismodegib Pulse Therapy on the Incidence of Newly Diagnosed Basal Cell Carcinomas (BCC)</title>
          <description>Measured by the incidence of biopsy confirmed BCC over a 24 month period</description>
          <population>Early study termination due to low accrual. No data analyzed; no results.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Incidence of Newly Diagnosed Squamous Cell Carcinomas (SCC) in the Same Subjects Receiving Vismodegib Treatment When Compared With Placebo</title>
        <description>Measured by the incidence of biopsy confirmed SCC over the same 24 month period</description>
        <time_frame>24 Months</time_frame>
        <population>Early study termination due to low accrual. No data analyzed; no results.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>receive 150 mg of oral placebo daily for a period of 2 months&#xD;
Placebo: Pulse therapy pattern of 2 months of daily treatment and 2 months of no treatment for 24 months.</description>
          </group>
          <group group_id="O2">
            <title>Vismodegib</title>
            <description>receive 150 mg of vismodegib daily for a period of 2 months&#xD;
Vismodegib: Pulse therapy pattern of 2 months of daily treatment and 2 months of no treatment for 24 months.</description>
          </group>
        </group_list>
        <measure>
          <title>The Incidence of Newly Diagnosed Squamous Cell Carcinomas (SCC) in the Same Subjects Receiving Vismodegib Treatment When Compared With Placebo</title>
          <description>Measured by the incidence of biopsy confirmed SCC over the same 24 month period</description>
          <population>Early study termination due to low accrual. No data analyzed; no results.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>receive 150 mg of oral placebo daily for a period of 2 months&#xD;
Placebo: Pulse therapy pattern of 2 months of daily treatment and 2 months of no treatment for 24 months.</description>
        </group>
        <group group_id="E2">
          <title>Vismodegib</title>
          <description>receive 150 mg of vismodegib daily for a period of 2 months&#xD;
Vismodegib: Pulse therapy pattern of 2 months of daily treatment and 2 months of no treatment for 24 months.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Taste disturbance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Leg cramps</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Scale in ear</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Amy Selegue</name_or_title>
      <organization>University of Arizona</organization>
      <phone>520-626-0301</phone>
      <email>aselegue@email.arizona.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

